You cannot apply for this job anymore (deadline was 11 Dec 2022).
Browse the current job offers or choose an item in the top navigation above.
The DOLPHIN project is an international multidisciplinary public private partnership project lead by Remond Fijneman (Translational Gastrointestinal Oncology, NKI) in close collaboration with Niels Kok (Surgery, NKI), Max Lahaye (Radiology, NKI), Jeanine Roodhart (Medical Oncology, UMCU), Manon Braat (Radiology, UMCU), Geraldine Vink (UMCU and PLCRC), Veerle Coupé (Health Technology Assessment, AUMC) and the company Delfi Diagnostics (Baltimore, USA).
You will coordinate the DOLPHIN study, which makes use of the infrastructure of the Dutch Prospective ColoRectal Cancer cohort study PLCRC. You will bring together clinical, imaging and molecular data and investigate the clinical utility of ctDNA testing for treatment response monitoring in patients with metastatic colorectal cancer.
Fixed-term contract: 4 years.
You will join a dynamic international research team and will collaborate with clinicians and scientists with expertise in different disciplines. You will have the opportunity to follow high-quality courses offered by the OOA oncology graduate school throughout your PhD.
Your temporary employment will be for a period of four years. The gross salary per month will be according to the standard PhD scales starting from €2972,- to a maximum of €3620,- . The salary will depends on previous experience. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals).
The Netherlands Cancer Institute is among the world’s best comprehensive cancer centers, combining innovative fundamental, translational, and clinical research with dedicated patient care. Our research institute gratefully acknowledges funding from the Dutch Ministry of Health, Welfare and Sport, the Dutch Cancer Society, and individual donors. Read more about us.
The Netherlands Cancer Institute
Plesmanlaan 125, 1066 CX, Amsterdam
We like to make it easy for you, sign in for these and other useful features: